Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Kabbinavar, F. F.; Miller, V. A.; Johnson, B. E.; O'Connor, P. G.; Soh, C.; for the ATLAS Investigators |
| Abstract Title: | Overall survival (OS) in ATLAS, a phase IIIb trial comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy (chemo) with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) |
| Meeting Title: | 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 28 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2010 Jun 4-8 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2010-05-20 |
| Start Page: | 544s |
| Language: | English |
| ACCESSION: | WOS:000208852004661 |
| DOI: | 10.1200/jco.2010.28.15_suppl.7526 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 7526 -- Source: Wos |
